



Dedicated To Life

January 15, 2026

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated January 15, 2026, titled "**Zydus receives final approval from USFDA for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives final approval from USFDA for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg

Ahmedabad, India, 15 January, 2026

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg (USRLD: Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg).

Eltrombopag tablets are indicated for the treatment of thrombocytopenia (low platelet count) in specific blood disorders. Eltrombopag works by stimulating bone marrow cells to produce more platelets, thereby reducing the risk of bleeding.

Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Eltrombopag tablets had annual sales of USD 1262.5 mn in the United States (IQVIA MAT Nov-2025).

The group now has 429 approvals and has so far filed 505* ANDAs since the commencement of the filing process in FY 2003-04.

*(*As on 31-Dec-2025)*



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878